• 1. Clinical Administration Characteristics of Subcutaneous and …

  ascopubs.org

  Link: https://ascopubs.org/doi/10.1200/OP.22.00421

  Description: WEBFeb 9, 2023 · DARA IV administration is expected to take a median of 7 hours for the first dose and decrease for subsequent doses 8; our findings confirmed that initial dose …

  DA: 27 PA: 32 MOZ Rank: 35

• 2. An overview of turoctocog alfa pegol (N8-GP; …

  nih.gov

  Link: https://pubmed.ncbi.nlm.nih.gov/31809565/

  Description: WEBFactor replacement therapy with factor VIII (FVIII) concentrates is the current standard of care for patients with haemophilia A. Postadministration monitoring of FVIII activity … Author: Mirella Ezban, Martin Hansen, Marianne Kjalke Publish Year: 2020

  Author: Mirella Ezban, Martin Hansen, Marianne KjalkePublish Year: 2020

  DA: 44 PA: 24 MOZ Rank: 68

• 3. Work Interruption Experienced by Nurses during …

  nih.gov

  Link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5735655/

  Description: WEBNov 20, 2017 · The nursing medication administration process involves the preparation, administration, and documentation in a continuous process through a series of actions … Author: Mehammed Adem Getnet, Berhanu Boru Bifftu Publish Year: 2017

  Author: Mehammed Adem Getnet, Berhanu Boru BifftuPublish Year: 2017

  DA: 89 PA: 88 MOZ Rank: 56

• 4. An in vivo strategy to counteract post-administration

  nature.com

  Link: https://www.nature.com/articles/ncomms15242

  Description: WEBOpen access. Published: 19 May 2017. An in vivo strategy to counteract post-administration anticoagulant activity of azido-Warfarin. Sylvain Ursuegui, Marion … Author: Sylvain Ursuegui, Marion Recher, Wojciech Krężel, Alain Wagner Publish Year: 2017

  Author: Sylvain Ursuegui, Marion Recher, Wojciech Krężel, Alain WagnerPublish Year: 2017

  DA: 47 PA: 12 MOZ Rank: 70

• 5. An overview of turoctocog alfa pegol (N8‐GP; …

  wiley.com

  Link: https://onlinelibrary.wiley.com/doi/10.1111/hae.13897

  Description: WEBOpen Access. An overview of turoctocog alfa pegol (N8-GP; ESPEROCT®) assay performance: Implications for postadministration monitoring. Mirella Ezban, . … Author: Mirella Ezban, Martin Hansen, Marianne Kjalke Publish Year: 2020

  Author: Mirella Ezban, Martin Hansen, Marianne KjalkePublish Year: 2020

  DA: 6 PA: 71 MOZ Rank: 58

• 6. A Nanostrategy for Efficient Imaging‐Guided Antitumor …

  wiley.com

  Link: https://onlinelibrary.wiley.com/doi/full/10.1002/advs.201903243

  Description: WEBJan 31, 2020 · The Gd(III) content in the heart, liver, spleen, lung, kidney, and tumor of tumor-bearing mice at 24 h postadministration of Gd-DTPA is shown in Figure 5b. The highest Gd(III) content is found in the kidney …

  DA: 62 PA: 89 MOZ Rank: 97

• 7. Efficacy of oral midazolam for minimal and moderate …

  nih.gov

  Link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6900062/

  Description: WEBOct 14, 2019 · Sedation 5‐point scale (3 = drowsy or 2 = light sleep, 30 min postadministration) a: B: 1‐10 y: ASA I‐II: Oral midazolam (extemporaneous …

  DA: 75 PA: 90 MOZ Rank: 20

• 8. Factor VIII chromogenic assays can be used for potency …

  sciencedirect.com

  Link: https://www.sciencedirect.com/science/article/pii/S153878362203536X

  Description: WEBAug 1, 2016 · Objectives. To evaluate available chromogenic assay kits for potency labeling of polyethylene glycol–glycoconjugated turoctocog alfa (turoctocog alfa pegol [N8‐GP]) …

  DA: 64 PA: 6 MOZ Rank: 24

• 9. Biodistribution of Graphene Oxide Determined through …

  nih.gov

  Link: https://pubmed.ncbi.nlm.nih.gov/32856458/

  Description: WEBOct 20, 2020 · Biodistribution of Graphene Oxide Determined through Postadministration Labeling with DNA-Conjugated Gold Nanoparticles and ICPMS. Anal Chem. 2020 Oct …

  DA: 24 PA: 24 MOZ Rank: 51